Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The firm maintains its Buy rating on the stock with an upside potential of almost 207%.

The adjustment follows updates to the firm’s model, which raised its estimates for claseprubart. Guggenheim now projects approximately $2.8 billion in global peak sales from CIDP patients and estimates around $2 billion in global sales from the gMG indication.

On January 29, Oppenheimer increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $125 from $62 while maintaining an Outperform rating. The firm points out that Dianthus shares have gained 22% year to date, compared with XBI’s 5% rise. This is primarily due to the comments from CEO Marino Garcia during the January healthcare conference on the potential superiority of the company’s product over the competitor’s complement inhibitors.

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company dedicated to transforming the treatment of severe autoimmune and inflammatory diseases. They specialize in engineering highly selective monoclonal antibodies, such as their lead candidate claseprubart, to improve upon existing complement therapies. Their focus is on delivering potent, patient-friendly, and convenient treatment options.

While we acknowledge the potential of DNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.